Homocysteine and methylenetetrahydrofolate reductase in subjects undergoing coronary angiography;Homocistéina e metilenotetrahidrofolato redutase em indivíduos submetidos à angiografia coronariana

Arquivos Brasileiros de Cardiologia

Volumn 88, Issue 2, 2007, Pages

  Lima, Luciana Moreira ^a   Carvalho, Maria Das Graças ^a   Fernandes, Ana Paulo ^a   Sabino, Adriano De Paula ^a   Loures Vale, Andréia Assis ^a   Neto, Cirilo Pereira Da Fonseca ^a   Garcia, José Carlos Faria ^a   Saad, Jamil Abdala ^a   Sousa, Marinez Oliveira ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Coronary angiography; Homocysteine; Methylenetetrahydrofolate reductase (MTHFR)

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMATOSIS; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY ATHEROSCLEROSIS; ENZYMOLOGY; GENETICS; HOSPITALIZATION; MIDDLE AGED; POINT MUTATION; RISK FACTOR;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POINT MUTATION; POLYMORPHISM, GENETIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 33947608269     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2007000200006     Document Type: Article

References (38)

1. Falk E, Zhou J, Moller J. Homocysteine and atherothrombosis. Lipids. 2001; 36 (Suppl. 1): S3-S11.
2. Guilland JC, Favier A, De Courcy PG, Galan P, Hercberg S. Hyperhomocysteinemia: an independent risk factor or a simple marker of vascular disease? Pathol Biol (Paris). 2003; 51:101-10.
3. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard C, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10: 111-3.
4. Boushey CI, Beresford SA, Omenn GS, Matulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for cardiovascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274: 1049-57.
5. Murphy-Chutorian D, Alderman EL. The case that hyperhomocysteinemia is a risk factor for coronary artery disease. Am J Cardiol. 1994; 73: 705-7.
6. Nehler MR, Taylor LM, Porter JM. Homocysteinemia as a risk factor for atherosclerosis: a review. Cardiovasc Pathol. 1997; 6: 1-9.
7. Nygärd O, Nordrehaug JA, Refsum HS. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Eng J Med. 1997; 337: 230-6.
8. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997; 277: 1775-81.
9. Puri A, Gupta OK, Dwivedi RN, Bharadway RP, Narain VS, Singh S. Homocysteine and lipid levels in young patients with coronary artery disease. J Assoc Physicians India. 2003; 51: 681-5.
10. Gupta M, Sharma P, Garg G, Kaur K, Bedi GK, Vig A. Plasma homocysteine: an independent or an interactive risk factor for coronary artery disease. Clin Chim Acta. 2005; 352: 121-5.
11. Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa I. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med. 2004; 140: 94-100.
12. Kazemi MB, Eshraghian K, Omrani GR, Lankarani KB, Hosseini E. Homocysteine level and coronary artery disease. Angiology. 2006; 57: 9-14.
13. Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem. 2003; 36: 431-41.
14. Folson AR, Nieto FJ, McGovem PG, Tsai MY, Malinow MR, Eckfeldt JH, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphism, and B vitamins. The Atherosclerotic Risk in Communities (ARIC) Study. Circulation. 1998; 98: 204-10.
15. Nikfardjam M, Graf S, Hornykewycz S. Homocysteine plasma levels in young patients with coronary artery disease. Relation to history of acute myocardial infarctation and anatomical extent of disease. Thromb Res. 2001; 103 (Suppl. 1): 35-9.
16. Sociedade Brasileira de Cardiologia. III Diretrizes Brasileiras Sobre Dislipidemias e Diretrizes de Prevenção da Aterosclerose. Arq Bras Cardiol. 2001; 77 (Suppl. 3): 1-48.
17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; 26 (Suppl. 1): S5-20.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003; 289: 2560-72.
19. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices. 2nd ed. Tentative Guideline. NCCLS Document EP5-T2, 1992.
20. Voutilainen S, Lakka TA, Hamelahti P, Lehtimaki T, Pousen HE, Salonen JT. Plasma total homocysteine concentration and risk of acute coronary events: the Kuopio Ischemic Heart Disease Risk Factor Study. J Intern Med. 2000; 248: 217-22.
21. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA. 2003; 100: 177-82.
22. Chua S, Wu CJ, Chang HW, Hang CL, Chen CJ, Yang CH, et al. Impact of elevated plasma total homocysteine concentration on coronary atherosclerosis in Chinese patients with acute myocardial infarctation undergoing primary coronary intervention. Int Heart J. 2005; 46: 181-93.
23. Bostom A, Selhub J. Homocysteine and arteriosclerosis: subclinical and clinical disease associations. Circulation. 1999; 99: 2361-3.
24. Malinow MR, Bostom AG, Krauss RM. Homocysteine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1999; 99: 178-82.
25. Christen W, Ajani U, Glynn R. Blood levels of homocysteine and increased risks of cardiovascular disease. Causal or casual? Arch Intern Med. 2000; 169: 422-34.
26. Girelli D, Martinelli N, Pizzolo F, Friso S, Olivieri S, Stranieri C, et al. The interaction between MTHFR 677 C??T genotype and folate status is a determinant of coronary atherosclerosis risk. J Nutr. 2003; 133: 1281-5.
27. Stangl V, Baumann G, Stangl K. Coronary atherogenic risk factor in women. Eur Heart J. 2002; 23: 1738-52.
28. Duell PB, Malinow MR. Homocysteinemia and risk of atherosclerosis: a clinical approach to evaluation and management. Endocrinologist. 1998; 8: 170-7.
29. Malinow M. Hyperhomocysteinemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation. 1990; 81: 2004-6.
30. Yang F, Tan HM, Wang H. Hyperhomocysteinemia and atherosclerosis. Acta Physiol Sinica. 2005; 57: 103-14.
31. Gravina-Taddei CF, Batlouni M, Sarteschi C, Baltar VT, Salvarini NA, Bertolami MC, et al. Hiper-homocisteinemia como fator de risco para doença aterosclerótica coronariana em idosos. Arq Bras Cardiol. 2005; 85: 166-73.
32. Arruda VR, Siqueira LH, Gonçalves MS, von Zuben PM, Soares MC, Menezes R, et al. Prevalence of the mutation C677T in the methylenetetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Gen 1998; 78: 332-5.
33. Pisciotta L, Cortese C, Gnasso A, Liberatoscioli L, Pastore A, Mannucci L, et al. S. Serum homocysteine, methylenetetrahydrofolate reductase gene polymorphism and cardiovascular disease in heterozygous familial hypercholesterolemia. Atherosclerosis. 2005; 179: 333-8.
34. Dedoussis GY, Panagiotakos DB, Chrysohoou C, Pitsavos C, Zampelas A, Choumerianou D, et al. Effect of interaction between adherence to a Mediterranean diet and the methylenetetrahydrofolate reductase 677C→T mutation on homocysteine concentrations in health adults: the ATTICA Study. Am J Clin Nutr. 2004; 80: 849-54.
35. Yilmaz H, Isbir S, Agachan B, Ergren A, Farsak B, Isbir T. C677T mutation of methylenetetrahydrofolate reductase gene and serum homocysteine levels in Turkish patients with coronary artery disease. Cell Biochem Funct. 2006; 24 (1): 87-90.
36. Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from Northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood. 1998; 11: 4158-63.
37. Almawi WY, Ameen G, Tamim H, Finan RR, Irani-Hakime N. Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographycally documented coronary artery disease. J Thromb Thrombolysis. 2004; 17: 199-205.
38. Kölling K, Ndrepepa G, Koch W, Braun S, Mehilli J, Schomig A, et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. Am J Cardiol. 2004; 93: 1201-6.